Physician profile
Kent N Cunningham
NPI 1508839606
$14,076.26
in general payments reported to CMS, 2019-2025
43 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $1,488 · 2021: $1,435 · 2022: $2,240 · 2023: $2,198 · 2024: $2,469 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,969 · Education: $34.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,968.76 |
| Education | $34.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,583.33 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,107.93 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $876.70 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $748.12 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $639.75 | 2020-2025 | Linzess |
| Pfizer INC. | $565.86 | 2019-2025 | |
| Lilly USA, LLC | $490.47 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $370.68 | 2019-2025 | Sutab, Suflave |
| Daiichi Sankyo INC. | $333.43 | 2020-2025 | Injectafer |
| Genzyme Corporation | $321.93 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $274.10 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $254.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $246.77 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $219.09 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $216.85 | 2021-2024 | Sucraid, Sucraid |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $201.20 | 2019-2024 | Krystexxa, Avsola, Amjevita |
| Ambu INC. | $168.87 | 2020 | |
| Celgene Corporation | $168.03 | 2022-2024 | Zeposia |
| Medtronic, INC. | $156.54 | 2021 | |
| Boston Scientific Corporation | $151.84 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $149.55 | 2019-2025 | Ocaliva |
| Lucid Diagnostics INC. | $147.40 | 2024 | |
| Nestle Healthcare Nutrition INC. | $146.31 | 2021-2023 | |
| Allergan, INC. | $133.52 | 2019-2020 | |
| Novo Nordisk INC | $127.70 | 2019-2025 | Wegovy |
| Endogastric Solutions, INC | $116.08 | 2022 | |
| Exact Sciences Corporation | $115.00 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $109.58 | 2019-2025 | Rebyota, Clenpiq |
| Aimmune Therapeutics, INC. | $107.21 | 2024-2025 | Zenpep, Vowst |
| Glaxosmithkline, LLC. | $98.23 | 2025 | Arexvy |
| Redhill Biopharma INC. | $93.45 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Ardelyx, INC. | $93.04 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $78.26 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $74.79 | 2025 | Dupixent |
| Romark Laboratories, Lc | $73.55 | 2019 | |
| Biocon Biologics INC | $60.94 | 2024-2025 | Hulio, Yesintek |
| Neuraxis, INC. | $46.43 | 2025 | |
| Gilead Sciences, INC. | $45.53 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $43.34 | 2023 | Idacio |
| Shionogi INC | $39.49 | 2019 | |
| Celltrion USA INC. | $34.02 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $29.52 | 2025 | Iqirvo |
| Ucb, INC. | $17.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.